Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study

Kidney International

Volumn 49, Issue 1, 1996, Pages 163-167

  Delmez, James A ^a,b   Kelber, Jacobo ^a   Norword, Kathryn Y ^a   Giles, Karla S ^a   Slatopolsky, Eduardo ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 8129 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCI MIX; CALCITRIOL; CALCIUM CARBONATE; MAGNESIUM CARBONATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; MALE; PRIORITY JOURNAL;

EID: 0030064387     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.22     Document Type: Article

References (31)

1. DELMEZ JA, SLATOPOLSKY E: Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19:303-317, 1992
2. DELMEZ JA, SLATOPOLSKY E, MARTIN KJ, GEARING BN, HARTER HR: Minerals, vitamin D and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int 21:862-867, 1982
3. HOU SH, ZHAO J, ELLMAN CF, HU J, GRIFFIN Z, SPIEGEL DM, BOURDEAU JE: Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 18:217-224, 1991
4. ELLIOTT HL, DRYBURGH F, FELL GS, SABET S, MACDOUGALL AI: Aluminum toxicity during regular hacmodialysis. Br Med J 1978:1101-1103, 1978
5. PARKINSON IS, WARD MK, FEEST TD, FAWCETT RWP, KERR DNS: Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey. Lancet 1:406-409, 1979
6. PLATTS MM, GOODE GC, HISLOP JS: Comparison of the domestic water supply and the incidence of fractures and encephalopathy in patients on home dialysis. Br Med J ii:657-660, 1977
7. CLARKSON EM, MCDONALD SJ, DE WARDENER HE: The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci (Lond) 30:425-438, 1966
8. PEI Y, HERCZ G, GREENWOOD C, SHERRARD D, SEGRE G, MANUEL A, SAIPHOO C, FENTON S: Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients. Kidney Int 41:1374-1382, 1992
9. MERIC F, YAP P, BIA MJ: Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 16:459-464, 1990
10. SLATOPOLSKY E, WEERTS C, NORWOOD K, GILES K, FRYER P, FINCH J, WINDUS D, DELMEZ J: Long term effects of calcium carbonate and 2.5 mEq/L calcium dialysate on mineral metabolism. Kidney Int 36:897-903, 1989
11. 3 on mineral metabolism in man. Am J Clin Nutr 30:1064-1069, 1977
12. MAI ML, EMMETT M, SHEIKH MS, SANTA ANA CA, SCHILLER L, FORDTRAN JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36:690-695, 1989
13. SHEIKH MS, MAGUIRE JA, EMMETT M, SANTA ANA CA, NICAR MJ, SCHILLER LR, FORDTRAN JS: Reduction of dietary phosphorus absorption by phosphorus binders: A theoretical in vitro and in vivo study. J Clin Invest 83:66-73, 1989
14. SCHAEFER K, SCHEER J, ASMUS G, UMLAUF E, HAGEMANN J, VON HERRATH D: The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: A comparative study. Nephrol Dial Transplant 6:170-175, 1991
15. MOKINIERE P, DJERAD M, BOUDAILLIEZ B, EL ESPER N, BOITTE F, WESTEEL PF, COMPAGNON M, BRAZIER M, ACHARD JM, FOURNIER A: Control of predialytic hyperphosphatemia by oral calcium acetate and Calcium carbonate. Nephron 60:6-11, 1992
16. DELMEZ JA, TINDIRA CA, WINDUS DW, NORWOOD KY, GILES KS, NIGHSWANDER TL, SLATOPOLSKY E: Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 3:96-102, 1992
17. FINE KD, SANTA ANA CA, PORTER JL, FORDTRAN JS: Intestinal absorption of magnesium from food and supplements. J Clin Invest 88:396-402, 1991
18. KELBER J, SLATOPOLSKY E, DELMEZ J: Acute effects of different concentrations of dialysate magnesium during high-efficiency dialysis, Am J Kidney Dis 24:453-460, 1994
19. ADAMS CF: Nutrititive Value of American Foods in Common Units. Washington, D.C., Agricultural Research Service, United States Department of Agriculture, 1975, Handbook No. 456
20. HRUSKA KA, KOPELMAN R, RUTHERFORD WE, KLAHR S, SLATOPOLSKY E: Metabolism of immunoreactive parathyroid hormone in the dog: The role of the kidney and the effects of chronic renal disease. J Clin Invest 56:39-48, 1975
21. GUILLOT AP, HOOD VL, RUNGE CF, GENNARI FJ: The use of magnesium-containing phosphate hinders in patients with end-stage renal disease on maintenance hemodialysis. Nephron 30:114-117, 1982
22. MACTIER RA, LEUNG ACT, HENDERSON IS, DOBBIE JW: Control of hyperphosphatemia in dialysis patients: Comparison of aluminum hydroxide, calcium carbonate, and magnesium trilisate. Dial Transplant 16:599-601, 1987
23. OE PL, LIPS P, VAN DER MEULEN J, DE VRIES PMJM, VAN BRONSWIJK H: Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin Nephrol 28:180-185, 1987
24. O'DONOVAN R, BALDWIN D, HAMMER M, MONIZ C, PARSONS V: Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet 1:880-882, 1986
25. MORINIERI: P, VINATIER I, WESTEEL PF: Magnesium hydroxide as a complementary aluminum-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis. Nephrol Dial Transplant 3:651-656, 1988
26. 2 as sole phosphate binder. Nephron 60:154-163, 1992
27. BACHRA BN, FISCHER HRA: The effect of some inhibitors on the nucleation and crystal growth of apatite. Calcif Tissue Res 3:269-279, 1969
28. BOSKEY AL, POSHNER AS: Effect of magnesium on lipid-induced calcification: An in vitro model of bone mineralization. Calcif Tissue Int 32:139-143, 1980
29. GONELLA M, BALLANTI P, ROCCA CD, CALABRESE G, PRATESI G, VAGELLI G, MAZZOTTA A, BONUCCI E: Improved bone morphology by normalizing serum magnesium in chronically hemodialyzed patients. Miner Electrol Metab 14:240-245, 1988
30. MEEMA HE, OREOPOULOS DG, RAPOPORT A: Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 32:388-394, 1987
31. 3 suppresses parathyroid hormone secretion from parathyroid cells in tissue culture. Endocrinology 117:2114-2119, 1985